Get the Stockscreener App
4.69
1.52%
0.07
After Hours:
4.71
0.02
+0.43%
Cytek Biosciences Inc stock is traded at $4.69, with a volume of 306.58K.
It is up +1.52% in the last 24 hours and up +16.96% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
See More
Previous Close:
$4.62
Open:
$4.62
24h Volume:
306.58K
Relative Volume:
0.39
Market Cap:
$602.90M
Revenue:
$201.49M
Net Income/Loss:
$-66.54M
P/E Ratio:
-9.0244
EPS:
-0.5197
Net Cash Flow:
$-8.88M
1W Performance:
+0.64%
1M Performance:
+16.96%
6M Performance:
+15.52%
1Y Performance:
+26.08%
1-Day Range:
$4.62
$4.699
1-Week Range:
$4.435
$4.699
52-Week Range:
$2.37
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.69 | 593.90M | 201.49M | -66.54M | -8.88M | -0.5197 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences (CTKB) Inspiring Confidence With Aurora CS System Updates - Yahoo Finance
Cytek Biosciences unveils 21-color T-cell kit to boost immunoprofiling workflows - Traders Union
Aug Action: Can Cytek Biosciences Inc sustain its profitabilityMarket Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Millennium Group reports 6.64M shares in Cytek Biosciences (CTKB) - Stock Titan
Cytek Biosciences streamlines drop charge optimization for small sample workflows - Traders Union
Stock Market Recap: Is Cytek Biosciences Inc stock showing strong momentumTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates - MSN
Cytek Biosciences, Inc. (8EQ.F) stock price, news, quote and history - Yahoo Finance UK
Tudor Investment Corp ET AL Invests $867,000 in Cytek Biosciences, Inc. $CTKB - MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives $5.38 Consensus PT from Analysts - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Vanguard realignment leaves Cytek (NASDAQ: CTKB) ownership at 0 after amendment - Stock Titan
Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist - sahmcapital.com
EPS Watch: What is the Moat Score of Cytek Biosciences Inc2026 Rallies & Smart Allocation Stock Reports - baoquankhu1.vn
Cytek Biosciences, Inc. (CTKB) Stock Forecasts - Yahoo Finance
Cytek Biosciences outlines $205M–$212M 2026 revenue target amid record Q4 and growth in recurring revenue - MSN
Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on December 30, 2024. - marketscreener.com
CTKB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cytek Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Topline Capital Management LLC Has $24.10 Million Position in Cytek Biosciences, Inc. $CTKB - MarketBeat
US Stocks Recap: How does Cytek Biosciences Inc compare to its peersMarket Growth Report & Real-Time Market Sentiment Reports - baoquankhu1.vn
Cytek Biosciences (CTKB) director converts 6,107 RSUs into common stock - Stock Titan
Cytek Biosciences (CTKB) CLO receives new options, 226,453 RSUs and stock from vesting - Stock Titan
Cytek Biosciences (NASDAQ: CTKB) SVP granted options, RSUs and sees RSU vesting - Stock Titan
Cytek Biosciences (CTKB) CEO awarded options, RSUs and surrenders shares for taxes - Stock Titan
Cytek Biosciences (CTKB) CFO receives new equity awards and RSU vesting - Stock Titan
Cytek Biosciences (CTKB) CTO granted stock options and 227,535 RSUs - Stock Titan
Cytek Biosciences (NASDAQ: CTKB) director gains 2,908 shares via RSU vesting - Stock Titan
Latest CTKB NewsAmberstone Biosciences Secures $12 Million ... - Stock Titan
Sell Signal: What is the Moat Score of Cytek Biosciences IncTrade Performance Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact - The Manila Times
Cytek Biosciences expands global reach with one year of Singapore operations - Traders Union
Cytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact - Bitget
Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference - Yahoo Finance
How The Cytek Biosciences (CTKB) Story Is Shifting With New Targets And 2026 Guidance - Yahoo Finance
Cytek Biosciences Balances Growth With Margin Strain - The Globe and Mail
Cytek Biosciences, Inc. (CTKB) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Royce & Associates LP Increases Holdings in Cytek Biosciences, Inc. $CTKB - MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives $5.50 Average PT from Brokerages - Defense World
CTKB SEC FilingsCytek Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Cytek Biosciences at TD Cowen Health Care: Strategic Growth Insights By Investing.com - Investing.com Canada
Cytek Biosciences at TD Cowen Health Care: Strategic Growth Insights - Investing.com India
Buyback Watch: What is the Moat Score of Cytek Biosciences IncStop Loss & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
CTKB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cytek Biosciences outlines cell sorting breakthroughs in webinar - Traders Union
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cytek (CTKB) Q4 2025 Earnings Call Transcript - AOL.com
Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results, Misses Estimates By $0.36 EPS - MarketBeat
Earnings call transcript: Cytek Biosciences Q4 2025 sees record revenue, EPS miss - Investing.com South Africa
Cytek Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytek Biosciences Inc Stock (CTKB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCombe William D. | Chief Financial Officer |
Jun 02 '25 |
Buy |
2.78 |
35,000 |
97,300 |
55,746 |
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):